Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE:FOF) Declares Monthly Dividend of $0.09
by Doug Wharley · The Cerbat GemCohen & Steers Closed-End Opportunity Fund, Inc. (NYSE:FOF – Get Free Report) declared a monthly dividend on Tuesday, September 22nd. Stockholders of record on Tuesday, November 10th will be given a dividend of 0.087 per share on Monday, November 30th. This represents a c) dividend on an annualized basis and a dividend yield of 8.4%. The ex-dividend date of this dividend is Tuesday, November 10th.
Cohen & Steers Closed-End Opportunity Fund Stock Down 0.2%
Cohen & Steers Closed-End Opportunity Fund stock traded down $0.03 on Wednesday, reaching $12.48. 24,740 shares of the stock were exchanged, compared to its average volume of 70,094. Cohen & Steers Closed-End Opportunity Fund has a twelve month low of $12.44 and a twelve month high of $15.04. The firm has a fifty day moving average price of $13.39 and a two-hundred day moving average price of $13.54.
About Cohen & Steers Closed-End Opportunity Fund
Cohen & Steers Closed-End Opportunity Fund (NYSE:FOF) is a diversified closed-end investment company managed by Cohen & Steers Capital Management. The fund seeks to provide investors with current income and total return through a portfolio of closed-end funds and other income-oriented investments.
The fund invests across a range of asset classes and strategies, including equity, fixed-income and real asset-focused closed-end funds. Its portfolio may include funds that invest in areas such as real estate, infrastructure, preferred securities, business development companies and other income-producing securities, allowing FOF to provide exposure to multiple market segments through a single investment vehicle.
FOF may invest in both U.S.
Recommended Stories
- Five stocks we like better than Cohen & Steers Closed-End Opportunity Fund
- These 4 Companies Are Monetizing AI Today
- Quantum and Rare Earths? Implications of the Pasqal/USAR Partnership
- Lockheed’s Stock Hasn’t Priced In Its Own Backlog—Boeing’s Might Already Have
- Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up?